KA
REGN icon

Kozak & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Kozak & Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.15K Hold
5
– – ﹤0.01% 341
2026
Q1 		$3.76K Hold
5
– – ﹤0.01% 336
2025
Q4 		$4.01K Hold
5
– – ﹤0.01% 323
2025
Q3 		$3.54K Hold
5
– – ﹤0.01% 347
2025
Q2 		$2.77K Hold
5
– – ﹤0.01% 331
2025
Q1 		$2.86K Hold
5
– – ﹤0.01% 335
2024
Q4 		$3.59K Hold
5
– – ﹤0.01% 319
2024
Q3 		$5.04K Hold
5
– – ﹤0.01% 273
2024
Q2 		$5.12K Hold
5
– – ﹤0.01% 268
2024
Q1 		$4.84K Buy
+5
New +$4.75K ﹤0.01% 278

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Kozak & Associates's REGN Position: Q2 2026 in Review

Kozak & Associates held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 5 shares worth $3.15K. The position accounts for ﹤0.01% of the portfolio, ranked #341.

Kozak & Associates first reported a position in REGN in Q1 2024 and has held it in 10 quarters since. The position peaked at $5.12K in Q2 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Kozak & Associates held 5 shares of Regeneron Pharmaceuticals worth $3.15K as of Q2 2026.
  • Kozak & Associates left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Kozak & Associates's portfolio in Q2 2026, its #341 holding.
  • Kozak & Associates first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Kozak & Associates's Regeneron Pharmaceuticals position peaked at $5.12K in Q2 2024.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Kozak & Associates's 13F filing for Q2 2026, filed 2 Jul 2026.